Non Opioid Analgesics: Paracetamol, NSAIDs and Aspirin

DCM 2101 · CNS Pharmacology

Non-Opioid Analgesics: Paracetamol, NSAIDs and Aspirin

Non-opioid analgesics are among the medicines most commonly prescribed, bought without prescription, and misused. Their familiarity is deceptive: a simple painkiller can cause fulminant liver failure, life-threatening gastrointestinal bleeding, acute renal injury, severe bronchospasm, fetal complications, or dangerous drug-drug interactions when chosen inappropriately.

The safe prescriber must always evaluate two critical questions before selecting an analgesic: “What is the specific pathophysiological mechanism of this pain?” and “What is this patient’s comprehensive risk profile?” The objective is not merely to lower a subjective pain score; it is to achieve effective analgesia while meticulously protecting the gastrointestinal tract, kidneys, cardiovascular system, hepatic function, and pregnancy viability.

Learning objectives

Differentiate the pharmacodynamics and pharmacokinetics of paracetamol, traditional NSAIDs, and COX-2 selective NSAIDs.
Explain the arachidonic acid cascade, cyclo-oxygenase (COX) inhibition, and prostaglandin physiology.
Detail the Mechanism of Action (MOA), indications, contraindications, adverse effects, and drug interactions for each major class.
Select an analgesic according to pain mechanism, patient comorbidities, and polypharmacy risks.
Recognise and manage acute toxicological emergencies: paracetamol poisoning, NSAID toxicity, and salicylate poisoning.
Apply rational, evidence-based prescribing principles and counsel patients safely.

1. Clinical Context: The Role of Non-Opioid Analgesics

Non-opioid analgesics are indicated for mild to moderate pain, antipyresis, and—specifically for NSAIDs and high-dose aspirin—inflammation. They form the foundational step of multimodal analgesia. However, they do not treat every pain mechanism equally and must be tailored to the etiology.

Pain pattern	Typical clinical examples	Pharmacological rationale & first-line approach
Nociceptive somatic	Muscle strain, simple fracture, postoperative wound, osteoarthritis	Paracetamol for baseline analgesia. An NSAID is added when localized inflammation is present and risk is acceptable. Immobilisation/physiotherapy as appropriate.
Inflammatory	Acute rheumatoid arthritis flare, acute gout, dysmenorrhoea, dental abscess	NSAIDs are highly efficacious here because prostaglandin-mediated peripheral sensitisation heavily drives the pain response.
Visceral / Colicky	Renal colic, biliary colic	Assess the cause and emergency surgical features. Parenteral NSAIDs (e.g., diclofenac) are highly effective in renal colic by reducing ureteric prostaglandin-mediated spasm.
Neuropathic	Diabetic peripheral neuropathy, post-herpetic neuralgia, radiculopathy	Paracetamol/NSAIDs lack efficacy for true nerve-injury pain. A specific neuropathic-pain approach (gabapentinoids, SNRIs, TCAs) is required.
Chronic pain	Persistent non-specific low-back pain, chronic widespread pain	Focus shifts to functional restoration. Prioritise exercise, rehabilitation, and psychosocial care. Avoid indefinite, unmonitored automatic refills of NSAIDs due to cumulative organ toxicity.

Pain is a symptom, not a diagnosis

Before prescribing an analgesic, vigorously screen for clinical red flags: trauma, systemic sepsis, acute surgical abdomen, neurovascular compromise, compartment syndrome, meningitis, myocardial ischaemia, ectopic pregnancy, malignancy, and suicidal self-harm. Relief of pain must never delay or replace the investigation of a life-threatening underlying cause.

2. Pathophysiology and Pharmacology of Cyclo-oxygenase (COX) Inhibition

Cellular injury or inflammatory cytokines activate the enzyme phospholipase A₂, which cleaves arachidonic acid from phospholipid cell membranes. Cyclo-oxygenase (COX) enzymes then rapidly convert arachidonic acid into unstable endoperoxides (PGG2, PGH2), which isomerases subsequently metabolize into active prostaglandins (PGE2, PGD2, PGF2α), prostacyclin (PGI2), and thromboxane A2 (TXA2). These lipid mediators orchestrate pain, fever, inflammation, gastric mucosal defence, renal hemodynamics, and platelet aggregation.

The COX Isoenzymes: Pharmacological Differentiation

COX-1 (Constitutive): Often termed the “housekeeping” enzyme. It is continuously expressed in most tissues. Crucially, it synthesises prostaglandins that stimulate gastric mucus/bicarbonate production, maintain renal afferent arteriolar vasodilation, and produce platelet thromboxane A2 (promoting platelet aggregation and vasoconstriction).
COX-2 (Inducible): Primarily induced at sites of tissue damage and inflammation by cytokines (IL-1, TNF-α). It generates prostaglandins (PGE2) that sensitise peripheral nociceptors, cause local vasodilation, and act on the hypothalamus to elevate the thermoregulatory set point (causing fever). COX-2 is also constitutively present in the kidneys and vascular endothelium (producing PGI2, which inhibits platelets and vasodilates).
Traditional (Non-selective) NSAIDs: Inhibit both COX-1 and COX-2 to varying degrees. This dual blockade provides robust analgesia and anti-inflammatory effects but predictably strips away gastric protection and alters platelet function.
COX-2 Selective NSAIDs (Coxibs): Specifically designed to spare COX-1. They drastically reduce (but do not eliminate) upper gastrointestinal ulceration risk. However, they block endothelial PGI2 (a vasodilator/platelet inhibitor) while leaving platelet COX-1 (TXA2, a vasoconstrictor/pro-aggregator) unopposed. This imbalance can increase thrombotic cardiovascular risk (myocardial infarction, stroke).

The Leukotriene Shift: Inhibiting the COX pathway can shunt excess arachidonic acid down the Lipoxygenase (LOX) pathway. This increases the production of leukotrienes, which are potent bronchoconstrictors. This mechanism explains NSAID-exacerbated respiratory disease (AERD) or “aspirin-induced asthma” in susceptible individuals.

3. Paracetamol (Acetaminophen): Pharmacokinetics, Dynamics, and Toxicology

Paracetamol is a widely used analgesic and antipyretic. It is distinct from NSAIDs because it lacks significant anti-inflammatory activity in peripheral tissues.

Mechanism of Action (MOA)

The exact mechanism remains uniquely complex. It is a weak, reversible inhibitor of COX-1 and COX-2, acting almost exclusively in the central nervous system (CNS) where the peroxide tone is low. Peripheral sites of inflammation have high peroxide tone, which inactivates paracetamol’s COX-inhibiting ability. Additional proposed mechanisms include the inhibition of a central COX-3 splice variant, activation of descending serotonergic inhibitory pain pathways, and metabolism into AM404, which enhances the endogenous cannabinoid system and acts on TRPV1 receptors.

Pharmacokinetics

Absorption: Rapid and almost complete from the GI tract (peak plasma concentration in 30–60 minutes).
Distribution: Widely distributed; minimal protein binding (10-25%).
Metabolism: Extensively metabolised in the liver. At therapeutic doses, >90% undergoes Phase II conjugation (glucuronidation and sulfation) into non-toxic metabolites. Approximately 5% undergoes Phase I oxidation via Cytochrome P450 (specifically CYP2E1) into the highly reactive, toxic intermediate N-acetyl-p-benzoquinone imine (NAPQI). Glutathione immediately binds and neutralises NAPQI.
Excretion: Renal excretion of the conjugated metabolites.

Indications

First-line for mild-to-moderate nociceptive pain and fever.
Analgesic of choice in patients with peptic ulcer disease, bleeding disorders, asthma (AERD), or established cardiovascular disease.
Analgesic of choice during all trimesters of pregnancy.

Contraindications & Cautions

Absolute: Hypersensitivity to paracetamol; severe active hepatic failure.
Caution: Chronic severe malnutrition (depleted glutathione), chronic alcoholism (induces CYP2E1, increasing NAPQI formation), severe renal impairment (prolongs metabolite half-life).

Adverse Effects & Interactions

Adverse effects: Extremely rare at therapeutic doses. Very rarely associated with severe cutaneous adverse reactions (Stevens-Johnson Syndrome / TEN).
Interactions: Chronic use combined with Warfarin may mildly elevate the INR. Enzyme inducers (e.g., phenytoin, carbamazepine, rifampicin, chronic alcohol) increase CYP2E1 activity, raising the risk of hepatotoxicity even at high-therapeutic doses.

Toxicology: Paracetamol Poisoning

In overdose, the Phase II conjugation pathways become saturated. The drug is shunted to CYP2E1, creating massive amounts of NAPQI. Hepatic glutathione stores are rapidly depleted. Free NAPQI covalently binds to hepatocyte macromolecules, causing centrilobular hepatic necrosis and fulminant liver failure.

Clinical Presentation: Early symptoms (0-24 hours) are alarmingly mild (anorexia, nausea, pallor). Liver transaminases (AST/ALT) begin to surge at 24-72 hours, leading to right upper quadrant pain, jaundice, coagulopathy, hepatic encephalopathy, and death.
Assessment: “No symptoms” does not equal “no danger.” Clarify the formulation, timing, exact dose, and co-ingestants.
Management: Plot the timed serum paracetamol concentration (drawn at least 4 hours post-ingestion) on the Rumack-Matthew Nomogram. If the level is above the treatment line, promptly administer the antidote N-acetylcysteine (NAC). NAC acts primarily as a glutathione precursor, allowing the liver to detoxify NAPQI. Delaying NAC beyond 8 hours post-ingestion significantly increases the risk of hepatic necrosis.

4. Traditional and COX-2 Selective NSAIDs: Comprehensive Pharmacology

NSAIDs represent a heterogeneous group of organic acids. They provide analgesic, antipyretic, and anti-inflammatory efficacy by inhibiting COX enzymes.

Classification and Pharmacokinetics

Propionic acids: Ibuprofen, Naproxen. (Generally lower toxicity profile; Naproxen has a longer half-life).
Acetic acids: Diclofenac, Ketorolac, Indometacin. (Potent anti-inflammatories; Ketorolac is limited to max 5 days use due to extreme GI/renal toxicity).
Enolic acids (Oxicams): Piroxicam, Meloxicam. (Very long half-lives, suitable for once-daily dosing; Piroxicam has high GI risk).
Fenamates: Mefenamic acid. (Often preferred in dysmenorrhoea due to dual prostaglandin synthesis inhibition and receptor antagonism).
Selective COX-2 Inhibitors (Coxibs): Celecoxib, Etoricoxib. (Lower GI bleed risk, higher cardiovascular thrombotic risk).

Pharmacokinetics: NSAIDs are weak acids, well absorbed orally. They are highly protein-bound (>90% to albumin), undergo hepatic metabolism, and are renally excreted.

Indications

Inflammatory arthropathies (Rheumatoid arthritis, Ankylosing spondylitis).
Acute musculoskeletal injury, osteoarthritis flares.
Acute gouty arthritis (e.g., Indometacin, Naproxen).
Primary dysmenorrhoea (reduces uterine hypercontractility).
Medical closure of Patent Ductus Arteriosus (PDA) in neonates (Indometacin, Ibuprofen).

Contraindications

Active peptic ulceration or recent GI bleeding.
Severe heart failure, established ischaemic heart disease, or post-CABG surgery.
Chronic kidney disease (CKD) or acute kidney injury (AKI).
Third trimester of pregnancy: Risk of premature closure of the ductus arteriosus and oligohydramnios (fetal renal impairment).
History of asthma/bronchospasm triggered by aspirin (AERD).

Major Drug Interactions

Anticoagulants (Warfarin, DOACs) & SSRIs: Exponentially increases risk of fatal upper GI bleeding.
Methotrexate: NSAIDs reduce renal clearance of MTX, leading to potentially fatal bone marrow suppression.
Lithium: NSAIDs reduce lithium excretion, causing lithium toxicity (tremor, ataxia).
Anti-hypertensives: NSAIDs antagonize the blood-pressure-lowering effects of diuretics, ACE inhibitors, and beta-blockers by promoting sodium retention.

Understanding NSAID Adverse Effects by Organ System

Organ System	Pathophysiological Mechanism	Clinical Manifestations	Risk Mitigation Strategy
Gastrointestinal	COX-1 blockade eliminates PGE2/PGI2, reducing mucosal blood flow, mucus, and bicarbonate secretion while increasing acid.	Dyspepsia, asymptomatic micro-bleeding, massive haematemesis, melaena, gastric perforation.	Prescribe lowest effective dose for shortest duration. Co-prescribe a Proton Pump Inhibitor (PPI) for high-risk patients. Consider a COX-2 selective agent.
Renal	In hypovolemic states, renal perfusion relies on prostaglandin-mediated afferent arteriole vasodilation. NSAIDs block this, starving the glomerulus.	Acute kidney injury (AKI), fluid retention, peripheral oedema, hyperkalaemia, papillary necrosis (with chronic use).	Strictly avoid in dehydration, sepsis, advanced CKD, and uncompensated heart failure. Monitor creatinine.
Cardiovascular	COX-2 blockade reduces endothelial prostacyclin (vasodilator/anti-thrombotic) while leaving COX-1 thromboxane intact. Sodium retention raises BP.	Exacerbation of heart failure, refractory hypertension, increased risk of myocardial infarction and stroke.	Avoid coxibs and diclofenac in patients with high cardiovascular risk. Naproxen is generally considered the safest traditional NSAID for the heart.
Respiratory	Arachidonic acid shunting via the Lipoxygenase (LOX) pathway produces excess leukotrienes.	Severe bronchospasm, rhinitis, urticaria, anaphylaxis (Samter’s Triad).	Strictly avoid all NSAIDs in patients with a history of aspirin-sensitive asthma.

The Dangerous “Triple Whammy”

The concurrent use of an ACE inhibitor (or ARB) + a Diuretic + an NSAID is a recipe for catastrophic acute kidney injury. Mechanism:
1. Diuretic: Causes volume depletion, lowering overall renal perfusion.
2. NSAID: Blocks afferent arteriole vasodilation (constricting blood flow into the glomerulus).
3. ACEi / ARB: Blocks efferent arteriole vasoconstriction (dilating the exit, dropping filtration pressure).
The combined effect eliminates the kidney’s ability to maintain Glomerular Filtration Rate (GFR).

5. Aspirin (Acetylsalicylic Acid): Antiplatelet Actions and Analgesia

Aspirin is pharmacologically unique among NSAIDs. While it inhibits COX enzymes like others, its mechanism is irreversible.

Mechanism of Action and Pharmacokinetics

MOA: Aspirin covalently acetylates a specific serine residue (Serine 529 on COX-1; Serine 516 on COX-2), destroying the enzyme’s active site. Because platelets lack a nucleus, they cannot synthesize new COX-1 enzymes. Therefore, a single low dose of aspirin (75-150mg) eliminates platelet thromboxane A2 production for the entire 7-10 day lifespan of the platelet.
Dose-Dependent Pharmacodynamics:
- Low Dose (75–150 mg/day): Selective COX-1 inhibition; potent antiplatelet effect.
- Moderate Dose (300–1000 mg/day): Analgesic and antipyretic effect.
- High Dose (3–6 g/day): Anti-inflammatory effect (rarely used due to toxicity).
Pharmacokinetics: Rapidly hydrolyzed in plasma to salicylic acid. Crucially, at high anti-inflammatory doses, hepatic metabolic pathways become saturated, shifting elimination from first-order to zero-order kinetics. This means half-life drastically increases, and small dose increments cause massive spikes in blood levels.

Clinical Considerations and Adverse Effects

Indications: Secondary prevention of myocardial infarction, ischemic stroke, and transient ischemic attacks (TIAs). Acute management of coronary syndromes.
Contraindications: Haemophilia, active bleeding ulcers. Do not give to children or adolescents under 16 with viral illnesses (influenza, varicella) due to the high risk of Reye’s Syndrome (rapidly progressive encephalopathy and hepatic steatosis with high mortality).
Uricosuric Effect: Aspirin has a paradoxical dose-dependent effect on uric acid. Low doses (antiplatelet) decrease tubular secretion, precipitating gout. High doses decrease reabsorption, acting as a uricosuric.

6. Toxicology: NSAID Overdose and Salicylate Poisoning

NSAID Overdose (Ibuprofen, Diclofenac, Naproxen)

In stark contrast to paracetamol, most traditional NSAID overdoses are clinically benign. Massive ingestions may cause nausea, vomiting, epigastric pain, lethargy, and dizziness. Severe toxicity (seizures, metabolic acidosis, acute renal failure, coma) is rare but possible with massive doses of ibuprofen or mefenamic acid.

Management: Mainly supportive. ABCDE approach. Give activated charcoal if presentation is within 1 hour of a massive ingestion. Ensure adequate IV hydration to protect renal perfusion. Monitor U&Es and acid-base status. There is no specific antidote.

Salicylate Poisoning (Aspirin Overdose) – A Medical Emergency

Salicylates cause profound systemic toxicity by uncoupling oxidative phosphorylation in mitochondria, halting ATP production and generating massive amounts of heat. They also directly stimulate the medullary respiratory center.

Clinical Presentation: Classical early signs include tinnitus (ringing in the ears), vertigo, diaphoresis (sweating), hyperthermia, and vomiting.
Acid-Base Disturbance: Initially, direct respiratory center stimulation causes hyperventilation, resulting in a Respiratory Alkalosis. To compensate, kidneys excrete bicarbonate. Later, the accumulation of salicylic acid, lactic acid, and ketoacids causes a profound, life-threatening High Anion-Gap Metabolic Acidosis.
Management:
1. Resuscitation (ABCDE), correct dehydration and hypoglycaemia (brain glucose is rapidly depleted).
2. Activated charcoal if early.
3. Urinary Alkalinisation: Administer IV Sodium Bicarbonate. Raising urine pH > 7.5 ionizes the salicylic acid in the renal tubules, preventing its reabsorption (ion trapping) and drastically increasing its excretion.
4. Haemodialysis: Indicated for severe poisoning (levels > 700 mg/L, or > 500 mg/L with severe metabolic acidosis, renal failure, pulmonary oedema, or altered mental status).

Ventilation Warning in Salicylate Toxicity

If a patient with severe salicylate poisoning is intubated, the mechanical ventilator must be set to match their pre-intubation hyperventilation (very high minute volume). If ventilation is normalized, the patient will lose their compensatory respiratory alkalosis, systemic pH will plummet, and salicylic acid will rapidly cross the blood-brain barrier, causing immediate neurological death.

7. Clinical Decision-Making: Evidence-Based Case Applications

Case 1: 21-year-old with primary dysmenorrhoea, no medical history

Action: Prostaglandin F2α mediates painful uterine ischemia and hypercontractility. An NSAID (e.g., Ibuprofen, Naproxen, or Mefenamic acid) is the superior pharmacological choice. Start early at the onset of bleeding, use for 2-3 days, and take with food.

Case 2: 74-year-old with knee osteoarthritis, CKD Stage 3, and a past bleeding ulcer

Action: Systemic NSAIDs carry extreme risk here (GI bleed + acute-on-chronic renal failure). First-line therapies should include weight loss, physiotherapy, topical NSAIDs (which have minimal systemic absorption), and scheduled paracetamol. If an oral NSAID is absolutely necessary, a highly selective COX-2 inhibitor with a PPI might be discussed, but renal risk remains high.

Case 3: 45-year-old with a fever, tension headache, taking Warfarin for AF

Action: NSAIDs will disrupt the gastric mucosa and inhibit platelet function, exponentially increasing the risk of life-threatening gastrointestinal haemorrhage when combined with Warfarin. Paracetamol is the safest antipyretic/analgesic choice, though prolonged use at high doses should prompt INR monitoring.

8. The WHO Analgesic Ladder and Modern Multimodal Pain Management

The World Health Organization introduced the analgesic ladder in 1986, originally for cancer pain, but it has profoundly shaped general pain management.

Step 1 (Mild Pain): Non-opioid (Paracetamol, NSAID) +/- Adjuvant.
Step 2 (Moderate Pain): Weak opioid (Codeine, Tramadol) + Non-opioid +/- Adjuvant.
Step 3 (Severe Pain): Strong opioid (Morphine, Fentanyl) + Non-opioid +/- Adjuvant.

The Multimodal Concept: Modern practice dictates that non-opioids should be continued even when escalating to Step 2 or 3. By combining drugs with different mechanisms of action (e.g., Paracetamol [central] + NSAID [peripheral] + Opioid [receptor]), clinicians can achieve synergistic pain relief while significantly lowering the required dose—and thus the toxic side effects—of the opioid.

9. Rational Prescribing Checklist and Patient Education

Establish the Indication: What is the specific pathophysiological mechanism? Is an NSAID truly needed, or will paracetamol suffice?
Assess Patient Vulnerabilities: Age > 65, pregnancy status, hepatic function, eGFR, history of PUD, asthma status, and baseline blood pressure.
Reconcile Polypharmacy: Specifically check for the Triple Whammy (ACEi/ARB + Diuretic + NSAID), anticoagulants, antiplatelets, SSRIs, Methotrexate, and Lithium.
Formulate the Plan: Prescribe one systemic NSAID only. Use the lowest effective dose for the shortest viable duration. Co-prescribe PPI gastroprotection if indicated by local risk algorithms.
Educate the Patient: Warn against combining prescribed NSAIDs/Paracetamol with Over-The-Counter (OTC) cold and flu remedies (hidden duplication). Instruct them to stop the medication and seek immediate help if they develop black/tarry stools, vomit blood, experience facial swelling/wheezing, or notice a drastic reduction in urine output.

Knowledge check

1. Why do NSAIDs cause peptic ulceration?
They inhibit COX-1, halting the production of protective gastric prostaglandins (PGE2, PGI2), which reduces mucus secretion, bicarbonate production, and mucosal blood flow, leaving the epithelium vulnerable to gastric acid.

2. Explain the pathophysiological mechanism of the “triple whammy”.
An ACE inhibitor/ARB (dilates efferent arteriole) + a diuretic (reduces plasma volume) + an NSAID (constricts afferent arteriole). Together, they catastrophically drop glomerular capillary hydrostatic pressure, precipitating acute kidney injury.

3. What specific toxic metabolite is responsible for paracetamol-induced hepatotoxicity, and what enzyme produces it?
NAPQI (N-acetyl-p-benzoquinone imine), produced by the hepatic cytochrome P450 enzyme CYP2E1.

4. Why is low-dose aspirin pharmacologically distinct from ibuprofen in cardiovascular disease?
Aspirin irreversibly acetylates COX-1 in platelets, permanently disabling their ability to produce pro-aggregatory thromboxane A2 for their entire lifespan. Ibuprofen only provides reversible, temporary inhibition.

5. What is the classic initial acid-base disturbance in aspirin (salicylate) overdose?
Respiratory alkalosis, driven by direct toxic stimulation of the medullary respiratory center, which eventually progresses to a high anion-gap metabolic acidosis.

Further study and clinical references

Quick Quiz

Nonopioid Quiz

Pharmacology

Full Name Email Address

Privacy: Your details are used only for quiz tracking and certificates.